All Evaluable Patients to Date See Evidence of an Objective Response; Treatment Combination Associated with Statistically Significant Upregulation of PD-L1

Calgary, AB (Press Release) – Oncolytics Biotech^® Inc. ("Oncolytics") (TSX:ONC) (NASDAQ: ONCY) today announced that Dr. D.W. Sborov and colleagues made a poster presentation at the 15th Inter­na­tional Myeloma Workshop (IMW). The poster presentation, entitled "Combination Carfilzomib and the Viral On­co­lytic Agent REOLYSIN^® in Patients with Relapsed Multiple Myeloma: A Pilot Study Investigating Viral Pro­lifer­a­tion," discloses initial findings from a pilot study (NCI-9603) in patients with re­lapsed or refractory multiple …

New Treatment Combination with CTL019 Targets Precursors of Cancerous White Blood Cells

Philadelphia (Press Release) – A multiple myeloma patient whose cancer had stopped responding after nine dif­fer­en­t treat­ment regi­mens ex­peri­enced a com­plete remission after receiving an inves­ti­ga­tional per­son­al­ized cellular ther­apy known as CTL019 developed by a team at the University of Pennsylvania. The inves­ti­ga­tional treat­ment was com­bined with chemo­ther­apy and an au­tol­o­gous stem cell trans­plant – a new strat­egy designed to target and kill the cells that give rise to myeloma cells.

The team’s findings are published in a case report …

Study Met Primary Endpoint of Progression-Free Survival
Patients Receiving Kyprolis Lived Twice as Long Without Disease Progression

Thousand Oaks, CA and South San Francisco, CA (Press Release) – Amgen (NASDAQ: AMGN) and its sub­sid­i­ary Onyx Pharma­ceu­ticals, Inc., today announced the results from a planned interim analysis showing that the Phase 3 head-to-head clin­i­cal trial ENDEAVOR eval­u­ating Kyprolis® (car­filz­o­mib) for Injection in com­bi­na­tion with low-dose dexa­meth­a­sone versus Velcade® (bor­tez­o­mib) and low-dose dexa­meth­a­sone met the pri­mary end­point of pro­gres­sion-free survival (PFS). Patients with re­lapsed multiple myeloma treated with Kyprolis lived twice as long without their disease worsening, demonstrating statistically and clin­i­cally sig­nif­i­cant superiority over Velcade (median PFS 18.7 …

Cambridge, MA and Osaka, Japan (Press Release) – Takeda Pharma­ceu­tical Company Limited (TSE:4502) today announced that the ran­dom­ized, double-blind, placebo-controlled TOURMALINE-MM1 pivotal Phase 3 trial eval­u­ating the safety and efficacy of ixazomib, the first oral pro­te­a­some inhibitor, conducted in patients with re­lapsed or refractory multiple myeloma (MM) achieved its pri­mary end­point of im­prov­ing pro­gres­sion-free survival at the first pre-specified interim analysis. In the trial, patients treated with inves­ti­ga­tional ixazomib plus lena­lido­mide and dexa­meth­a­sone lived without their disease worsening for a sig­nif­i­cantly longer time compared to patients who received placebo plus lena­lido­mide/dexamethasone.

Efficacy …

– Data Featured as Oral Presentation at ASH 2014 –

San Francisco (Press Release) –Takeda Pharma­ceu­tical Company Limited (TSE:4502) today announced results from an open-label, Phase 2 study eval­u­ating the safety and efficacy of oral, single-agent ixazomib (MLN9708) as main­te­nance ther­apy in patients with multiple myeloma (MM) who had received ixazomib, lena­lido­mide and dexa­meth­a­sone as induction ther­apy. The data from this trial dem­onstrate the poten­tial feasibility of single-agent ixazomib main­te­nance ther­apy fol­low­ing 12 cycles of ixazomib-lenalidomide-dexamethasone, with deepening responses and an acceptable tolerability profile. These data were presented today at the 56th American Society of Hematology (ASH) …

• Results show statistically significant and clinically relevant increase in median progression-free survival with LBH589 plus bortezomib and dexamethasone[1]
• LBH589, a first-in-class treatment for patients with relapsed/refractory multiple myeloma if approved, helps extend benefit of standard-of-care therapy[1]
• First Phase III study to demonstrate superiority of a three-drug over two-drug combination in this patient population[1]
• Multiple myeloma, the second most common blood cancer, is incurable; most patients will relapse or become refractory so new treatments are needed[2],[3]

 …

Thousand Oaks, California and South San Francisco, California (Press Release) - Amgen (NASDAQ: AMGN) and its sub­sid­i­ary, Onyx Pharma­ceu­ticals, Inc., today announced that the Phase 3 clin­i­cal trial FOCUS (CarFilzOmib for AdvanCed Refractory MUltiple Myeloma European Study) did not meet its pri­mary end­point of im­prov­ing over­all survival (OS) (HR=0.975, 95 per­cent CI, 0.760, 1.249). The 315-patient, open-label study eval­u­ated single-agent Kyprolis® (car­filz­o­mib) for Injection compared to an active control regi­men of low-dose dexa­meth­a­sone, or equivalent corticosteroids, plus optional cyclo­phos­pha­mide in patients with re­lapsed and ad­vanced refractory multiple myeloma. Nearly all patients in …